ANDA 75566, held by Upsher-Smith Laboratories. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 75566 (Paroxetine Hydrochloride), held by Upsher-Smith Laboratories, was first approved by FDA on Mar 8, 2004, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 8, 2004 | Original application | Approved | None posted |
| Paroxetine HydrochlorideEQ 10MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 20MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 30MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 40MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Oct 26, 2009 | Supplement 7Labeling | Approved | None posted |
| Apr 21, 2009 | Supplement 6Labeling | Approved | None posted |
| May 17, 2005 | Supplement 4Labeling | Approved | None posted |
| Mar 8, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters